StromaForte by Swedish StromaBio for Cardiovascular Disease: Likelihood of Approval
StromaForte is under clinical development by Swedish StromaBio and currently in Phase II for Cardiovascular Disease. According to GlobalData, Phase II drugs for Cardiovascular Disease have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how StromaForte's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.StromaForte overviewThe therapeutic candidate is under development for the treatment of cardiovascular diseases, musculoskeletal injuries and degeneration, aging frailty and osteoarthritis. It consists of allogeneic bone marrow derived mesenchymal stromal cells (MSCs) administered through intravenous and intraarticular route.For a complete picture of StromaForte's drug-specific PTSR and LoA scores, buy the report here.
StromaForte is under clinical development by Swedish StromaBio and currently in Phase II for Cardiovascular Disease.
What's Your Reaction?
